HC Wainwright Has Negative Estimate for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for CervoMed in a research note issued to investors on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.92) per share for the quarter, down from their prior estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.62) EPS.

CRVO has been the topic of several other reports. Cantor Fitzgerald initiated coverage on shares of CervoMed in a report on Thursday, December 18th. They issued an “overweight” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research report on Wednesday, January 21st. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Finally, raised CervoMed to a “strong-buy” rating in a research report on Tuesday, February 3rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.00.

CervoMed Trading Down 5.0%

CRVO opened at $4.02 on Thursday. CervoMed has a 12-month low of $3.58 and a 12-month high of $16.94. The firm has a 50 day moving average of $5.13 and a two-hundred day moving average of $7.15. The firm has a market capitalization of $37.23 million, a PE ratio of -1.35 and a beta of -0.77.

CervoMed (NASDAQ:CRVO) last released its earnings results on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative return on equity of 96.04% and a negative net margin of 672.80%.The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.84 million.

Hedge Funds Weigh In On CervoMed

Several institutional investors have recently made changes to their positions in CRVO. XTX Topco Ltd acquired a new position in shares of CervoMed in the 4th quarter valued at $81,000. State Street Corp grew its position in CervoMed by 11.4% during the fourth quarter. State Street Corp now owns 20,527 shares of the company’s stock valued at $162,000 after buying an additional 2,100 shares during the period. Jane Street Group LLC purchased a new position in CervoMed in the fourth quarter valued at $88,000. HRT Financial LP purchased a new position in CervoMed in the fourth quarter valued at $113,000. Finally, Dimensional Fund Advisors LP purchased a new position in CervoMed in the fourth quarter valued at $110,000. 25.15% of the stock is owned by hedge funds and other institutional investors.

CervoMed News Roundup

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data from the AD/PD 2026 conference report that neflamapimod showed greater benefit in Dementia with Lewy Bodies (DLB) patients without Alzheimer’s co‑pathology — a result that supports the drug’s targeted efficacy and could improve the therapy’s commercial/clinical outlook if confirmed in later trials. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy stance with a $25 target and raised several quarterly and FY2026 EPS estimates (and raised some near-term quarter forecasts versus prior), which signals institutional support and more optimistic financial modeling from a biotech-focused analyst. MarketBeat: HC Wainwright Note
• Positive Sentiment: Chardan Capital published a note saying CervoMed’s stock price is expected to rise, providing an additional bullish voice among brokers that can attract speculative buyers. American Banking News: Chardan Note
• Neutral Sentiment: Brokers published FY2027 earnings predictions (mixed estimates across quarters); these model updates matter to valuation but contain no near-term guidance from management. American Banking News: FY2027 Predictions
• Neutral Sentiment: Short-interest reports posted anomalous/zero values (showing 0 shares and NaN changes), which appear to be data errors and therefore provide no clear signal about short pressure or potential squeezes. (Market participants should treat the short-interest data as unreliable until corrected.)
• Negative Sentiment: Roth MKM cut its price target to $11, which may weigh on sentiment among target‑driven investors and contributes to near‑term selling pressure. American Banking News: Roth MKM Target Cut

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.